Plasma Levels Correlate with Clinical Benefit

Slides:

Advertisements

Similar presentations

Robertson JFR et al. J Clin Oncol 2009;27(27):

Advertisements

Presented By Raymond Huang at 2014 ASCO Annual Meeting

results from the phase III TRIBE trial

MRC CR07: 5x5 TME vs. TME RCT in 3y Preop. RT + OP (n=674)

Major sites of GIST metastases:

Update on GIST Research

Measuring the benefit of palliative chemotherapy in women with platinum refractory/ resistant ovarian cancer Michael Friedlander Phyllis Butow, Martin.

Challenging Cases in Cancer: Integration of Findings from ASCO 2007 Gastrointestinal Stromal Tumors Charles D. Blanke, MD, FACP Associate Professor of.

NCCTG N9831 May 2005 Update Perez EA, Suman VJ, Davidson N, Martino S, Kaufman P, on Behalf of NCCTG, ECOG, SWOG, CALGB.

Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.

 Earliest possible diagnosis of the recurrence  Curative second-look surgery  Improved overall survival Follow-up The purpose of tumor markers.

Insert Program or Hospital Logo Introduction Melanoma is notoriously resistant to chemotherapy. While surgical resection and adjuvant chemotherapy can.

What are the main benefits of BRAF inhibitors in metastatic melanoma?

Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.

The Role of mTOR in Cancer Etiology and Treatment Based on presentations from the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)

OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-

Time to Secondary Resistance (TSR) After Interruption of Imatinib: Updated Results of the Prospective French Sarcoma Group Randomized Phase III Trial on.

Gemcitabine With or Without Cisplatin in Patients with Advanced or Metastatic Biliary Tract Cancer (ABC): Results of a Multicentre, Randomized Phase III.

CD-1 Second-line Chemotherapy for Hormone Refractory Prostate Cancer Disease Background Nicholas J. Vogelzang, MD Director Nevada Cancer Institute CD-1.

Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,

Early Treatment of Relapsed Ovarian Cancer Based on CA125 Level Alone Versus Delayed Treatment Based on Conventional Clinical Indicators Results of the.

Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting

Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.

Flowchart of participant screening, enrollment, withdrawal, and protocol completion Asterisk indicates those with partial or missing data included in analyses.

What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard

Presented By Luca Malorni at 2017 ASCO Annual Meeting

Joensuu H et al. Proc ASCO 2011;Abstract LBA1.

Attal M et al. Proc ASCO 2010;Abstract 8018.

ACOSOG Clinical Trials

Correlation between endogenous STAT5ab signaling and circulating plasma factors. Correlation between endogenous STAT5ab signaling and circulating plasma.

Surviving the First Year of Peritoneal Dialysis: Enduring Hard Times

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Table 2. Progression-Free Survival

Zaja F et al. Proc ASH 2010;Abstract 966.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

IL-18; IL-18BP; and free, biologically active IL-18 levels in nonsevere versus severe dengue cases. IL-18; IL-18BP; and free, biologically active IL-18.

PRISMA study flow diagram

Kaplan-Meier curves for overall survival (OS) probability.

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Supplementary Figure 2 Shiota et al.

Phase II trial of erlotinib in advanced pancreatic cancer

PFS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients (n=34). mPFS, median.

Forest plots for all drugs (OS and PFS HRs combined): excellent versus reduced PS comparison and ECOG PS levels comparison (see online supplementary 1). ECOG.

Cost Effectiveness of Intraoperative MRI for Treatment of High-Grade Gliomas Compared with neuronavigation systems, intraoperative MRI reliably maximizes.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular.

Plasma angiopoietin-like protein 4 (ANGPTL4) in healthy controls (Controls), patients with metabolic syndrome without (MetS−I) and with low-grade inflammation.

Josep M. Llovet, Robert Montal, Augusto Villanueva

OPN is elevated in patients with symptomatic AS

P aeruginosa-free survival curves analyzed by center and group using information either from all respiratory secretion cultures (A) or from specimens taken.

Headache frequency after medication withdrawal in medication-overuse headache. Headache frequency after medication withdrawal in medication-overuse headache.

Update on risk factors for food allergy

(A) The stratified analysis for DFS because of the uncertain status of HER2, 132 patients could be calculated the recurrence risk score. (A) The stratified.

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Unadjusted event-free survival (days alive and out-of-hospital) of participants with and without MCI in (A) overall cohort, (B) standard management cohort.

CXCL14-positive CAFs induce overexpression of LINC00092 in ovarian cancer. CXCL14-positive CAFs induce overexpression of LINC00092 in ovarian cancer. A,

Venous blood concentrations in nanograms of nicotine per millilitre (ng/ml) of plasma as a function of time for various nicotine delivery systems; all.

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

(A) Survival curves according to clinical response.

Overall and recurrence-free survival.

STK11/LKB1 genetic alterations are associated with shorter progression-free and overall survival with PD-1 blockade among KRAS-mutant LUAC in the SU2C.

Presentation transcript:

Plasma Levels Correlate with Clinical Benefit Subset Group (n=73) Q1 n=18 Q2-Q3 n=36 Q4 n=19 TPC Cmin <1110 ng/mL Cmin ≥1110 to <2040 ng/mL Cmin ≥2040 ng/mL OR 8 (44%) 24 (67%) 14 (74%) Median TTP 11.3 months 30.6 months 33.1 months TPC=trough plasma concentrations; OR=overall response; TTP=time to progression Adapted from: Demetri et al. ASCO-GI 2008, Study B2222.

Recurrence-free survival (%) ACOSOG Z9000: Overall Survival Recurrence-free survival (%) Adapted from: DeMatteo et al. GI ASCO 2008.

Recurrence-free survival (%) ACOSOG Z9000: Recurrence-free Survival Recurrence-free survival (%) Adapted from DeMatteo presentation at GI ASCO 2008.